Shots: The BT designation was based on two studies. The P-III ELEVATE-TN (ACE-CL-007) study involves assessing of Calquence as monothx. or in combination with obinutuzumab vs chlorambucil + obinutuzumab in […]readmore
Shots: The P-III ASCEND study results involve assessing of Calquence as monothx. (100mg, bid) vs Rituximab + Idelalisib (IdR) or Bendamustine (BR) in 310 patients in a ratio (1:1) with […]readmore
Shots: The P-III ELEVATE-TN trial involves assessing of Calquence (100 mg bid) as monothx and + obinutuzumab vs chlorambucil + obinutuzumab in 535 patients in ratio (1:1:1) with previously untreated […]readmore
Shots: The P-III ASCEND study involves assessing of Calquence (acalabrutinib, 100mg, q2d) vs Rituximab + Idelalisib/Bendamustine in 310 previously treated patients in a ratio (1:1) with CLL The P-III ASCEND […]readmore
Copyright © 2020 Digiqole. All Right Reserved.